Ann: Preliminary Final Report, page-17

Minimum requirement from Cap Raise to promote Evolis in various world markets including cost of manufacture: 7 million.
Oversubscribed by 2 million.
Another 1 million from a SPP, probably filled.
Now what was that about an orphan drug on page 22 of the July Investor Presentation.
And also under Objectives for 2018 in the April Investor Presentation.

This is the great thing about CDY, is its potential for a massive positive gamechanger coming out of left field that nobody was expecting.